These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24130396)

  • 1. Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder.
    Tikka SK; Garg S; Das B
    Indian J Pharmacol; 2013; 45(5):532-3. PubMed ID: 24130396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
    Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
    Reznik I; Sirota P
    Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dystonic reaction associated with fluvoxamine.
    George MS; Trimble MR
    J Clin Psychopharmacol; 1993 Jun; 13(3):220-1. PubMed ID: 8354740
    [No Abstract]   [Full Text] [Related]  

  • 6. Serotonin syndrome and fluvoxamine: a case study.
    Bastani JB; Troester MM; Bastani AJ
    Nebr Med J; 1996 Apr; 81(4):107-9. PubMed ID: 8628448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
    Jaffe RJ; Juneja NS; Juneja NS; Jaffe RJ; Coffey BJ
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):488-490. PubMed ID: 30226805
    [No Abstract]   [Full Text] [Related]  

  • 8. Hair loss associated with fluvoxamine use.
    Parameshwar E
    Am J Psychiatry; 1996 Apr; 153(4):581-2. PubMed ID: 8599419
    [No Abstract]   [Full Text] [Related]  

  • 9. Sulpiride addition in a case of fluvoxamine-refractory obsessive-compulsive disorder without comorbid psychopathology.
    Sevincok L; Uslu A; Kaynak H; Dereboy F
    J Psychiatry Neurosci; 2000 Mar; 25(2):185. PubMed ID: 10740992
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When fluvoxamine treats only depression and clomipramine treats only obsessive-compulsive disorder--combine them?
    Schaller JL; Behar D; Chamberlain T
    J Neuropsychiatry Clin Neurosci; 1998; 10(1):111-3. PubMed ID: 9547477
    [No Abstract]   [Full Text] [Related]  

  • 13. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
    Reznik I; Sirota P
    J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
    Mundo E; Guglielmo E; Bellodi L
    Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimal approach to the pharmacological management of obsessive-compulsive disorder?
    Ravindran AV
    J Psychiatry Neurosci; 1998 Mar; 23(2):136. PubMed ID: 9549253
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder.
    Harris E; Eng HY; Kowatch R; Delgado SV; Saldaña SN
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):347-53. PubMed ID: 20807074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine: safety profile in extensive post-marketing surveillance.
    Buchberger R; Wagner W
    Pharmacopsychiatry; 2002 May; 35(3):101-8. PubMed ID: 12107854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant-induced hypomania in obsessive-compulsive disorder.
    Rihmer Z; Barsi J; Belsõ N; Pestality P; György S
    Int Clin Psychopharmacol; 1996 Sep; 11(3):203-5. PubMed ID: 8923100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.